The STREET (Structured Efficient E-Tracking) Project for early COPD Diagnosis and Care.

<bold>The STREET (Structured Efficient E Tracking) Project for early COPD Diagnosis and Care.</bold> <bold>Background.</bold> About 30% of COPD diagnosis at first Spirometry are classified as GOLD 3-4 (Mapel et al. Int J COPD 2011), with a FEV1<50% of predicted, the more severe and resource consuming group. Therefore, improving early COPD diagnosis, ideally the GOLD 1 group (reported as <20%) is a strategic target. <bold>Aim.</bold> To promote in primary care setting quality-controlled spirometry (online verified by a Pulmonologist) on subjects at risk for COPD (i.e. with smoking habits ≥15 pack/years). <bold>Results.</bold> On 2150 screened subjects from April 2021 to December 2023, 387 with a post bronchodilator FEV1/FVC <0.7 were consecutively enrolled in a Real Life Observational Study (STructured Efficient E-Tracking, STREET project) to record the severity of COPD and, after 6 months, the therapy prescribed by General Practioners (GP) and patients'adherence. <table-wrap><object-id>erj;64/suppl_68/PA4322/T1</object-id><object-id>T1</object-id><object-id>t1</object-id><table><colgroup><col></col><col></col><col></col><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td>Grade</td><td>%</td><td>GOLD A, %</td><td>GOLD B, %</td><td>LAMA, %</td><td>LABA/LAMA, %</td><td>LABA/ICS, %</td></tr><tr><td>GOLD 1</td><td>15</td><td>85</td><td>15</td><td>18</td><td>0</td><td>0</td></tr><tr><td>GOLD 2</td><td>68</td><td>75</td><td>25</td><td>24</td><td>29</td><td>21</td></tr><tr><td>GOLD 3</td><td>14</td><td>82</td><td>18</td><td>0</td><td>73</td><td>27</td></tr><tr><td>GOLD 4</td><td>3</td><td>40</td><td>60</td><td>0</td><td>100</td><td>78</td></tr></tbody></table></table-wrap> None of the subjects was prescribed LABA alone, while salbutamol only was the drug of choiche in 72, 37, and 18% of COPD grade 1-2-3, respectively. MPR≥80% was detected in less than 30% of COPD GOLD grade 1-3. <bold>Conclusion.</bold> COPD GOLD grade 2-3 at first diagnosis were largely represented and GPs prescription of LABA/ICS was not compliant with the GOLD Document as none of the subjects was a frequent exacerbator, although it was not possible to detect if blood eosinophilia (>300 cells/µL) could have driven LABA/ICS prescription. Patients'adherence to inhaled therapy was low. GSK Supported Studies Program (ID 214326)